- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04798534
Intervention to Facilitate MMT/HIV Service Decentralization in Vietnam
May 27, 2023 updated by: Chunqing Lin, PhD, University of California, Los Angeles
Facilitating the Decentralization of Methadone Maintenance Therapy Services Into Communities in Vietnam
Vietnam is currently decentralizing its methadone maintenance therapy (MMT) dispensing network to its local commune health centers (CHC), which provides a window of opportunity to study decentralization of harm reduction and HIV-related healthcare services into community-based healthcare settings.
Commune health workers (CHW) in Vietnam have widespread misconceptions about harm reduction and perceived significant challenges associated with treating people who use drugs.
Intervention effort is needed to address these issues to ensure a smooth implementation of the decentralized service model.
This study is to pilot testing an intervention with a primary focus on process optimization in six CHC-based MMT distribution sites with 30 CHW and 90 MMT patients.
The six CHC in Thai Nguyen Province of Vietnam will be randomized to either an intervention condition or a control condition.
The intervention will be executed through a combination of in-person training and mobile phone application utilization.
The intervention outcomes on CHW and MMT clients will be evaluated at baseline, 3-, and 6-months.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The intervention pilot will be conducted in six commune health center (CHC)-based methadone maintenance therapy (MMT) distribution sites in Thai Nguyen Province of Vietnam.
Five commune health workers (CHW) and 15 MMT clients will be recruited from each of the CHC (total n = 30 CHW and 90 MMT clients).
The six CHC will be matched into pairs based on the current number of CHW and MMT patient load; and within each pair, the two CHC will be randomized into either a control condition or an intervention condition.
The intervention contents will include the promotion of streamlined procedure, skill training, problem solving, knowledge acquisition, networking and support, and information sharing.
The intervention will be delivered through a combination of service provider in-person training and mobile phone application utilization.
Provider-level outcomes (e.g., CHW's MMT/HIV service provision) and client-level outcomes (e.g., treatment progress) will be measured at baseline, 3-, and 6-month follow-ups.
Study Type
Interventional
Enrollment (Actual)
120
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Hanoi, Vietnam
- National Institute of Hygiene and Epidemiology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
MMT patients (n=90):
Inclusion criteria:
- Age 18 or over
- Currently seeking MMT services in one of the participating commune health centers
- Voluntary informed consent
Exclusion criteria:
- Having psychosis or neurological damage, or cannot understand the study purposes as judged by the recruiter in consultation with a clinic supervisor.
- Inability to give informed consent
CHW (n=30):
Inclusion criteria:
- Age 18 or over
- Currently working in one of the participating commune health centers and have direct contact with MMT clients
- Providing informed consent
Exclusion criteria:
• Inability to provide informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention group
CHW in the intervention arm will receive intervention through a combination of in-person training sessions and internet support.
MMT patients in the intervention arm can use a specially designed online platform to communicate with their CHW.
|
The intervention CHW will participate in three 60-minute intervention weekly sessions.
During the intervention, CHW will be provided with the knowledge and skills to serve their MMT patients.
The intervention sessions will also focus on enhancing the current service decentralization workflow so that the CHW can work with both their peer providers and their patients more efficiently.
Two-times booster sessions will be offered before the 3- and 6-month survey for continued skill building for problem-solving.
In addition to the group sessions, the intervention arm CHW will be encouraged to use a specially designed online platform to review the current policy and scientific findings, review their patients' treatment status, communicate with other providers, and provide instant consulting to their MMT patients.
The MMT patients in the intervention condition can use the online platform to communicate with their CHW and view education materials disseminated by their MMT providers or CHW.
|
No Intervention: Control group
The control group CHW will perform business as usual.
Both control group CHW and MMT patients do not have access to the online platform.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CHW's service provision for MMT providers
Time Frame: From baseline to 3-month
|
This outcome will be evaluated using the change in CHW's self-reported number of hours in a typical week they spend on providing services for their MMT patients in the following areas: treatment adherence and retention, physical and mental health, employment status, family issues, STI/HIV risk reduction, and healthcare utilization.
|
From baseline to 3-month
|
CHW's service provision for MMT providers
Time Frame: From baseline to 6-month
|
This outcome will be evaluated using the change in CHW's self-reported number of hours in a typical week they spend on providing services for their MMT patients in the following areas: treatment adherence and retention, physical and mental health, employment status, family issues, STI/HIV risk reduction, and healthcare utilization.
|
From baseline to 6-month
|
Patients' adherence to MMT
Time Frame: From baseline to 3-month
|
This outcome will be measured using the change in the number of days the client received an MMT dosage divided by the total number of days during an observation period.
Any occurrence of a special event (including termination of MMT, a positive urine test, and/or a dosage change) will be documented in detail.
|
From baseline to 3-month
|
Patients' adherence to MMT
Time Frame: From baseline to 6-month
|
This outcome will be measured using the change in the number of days the client received an MMT dosage divided by the total number of days during an observation period.
Any occurrence of a special event (including termination of MMT, a positive urine test, and/or a dosage change) will be documented in detail.
|
From baseline to 6-month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patients' level of satisfaction with community-based services
Time Frame: From baseline to 3-month
|
This outcome will be measured using the change in the Verona Service Satisfaction Scale for Methadone Treatment (VSSS-MT; Range: 7-28; higher score indicates higher level of service satisfaction)
|
From baseline to 3-month
|
Patients' level of satisfaction with community-based services
Time Frame: From baseline to 6-month
|
This outcome will be measured using the change in the Verona Service Satisfaction Scale for Methadone Treatment (VSSS-MT; Range: 7-28; higher score indicates higher level of service satisfaction)
|
From baseline to 6-month
|
Patients' service preference
Time Frame: From baseline to 3-month
|
This outcome will be measured by change in patients' indicated preference between centralized healthcare agencies and CHC when they have a list of hypothetical health conditions (including mental health issues, infectious diseases, when seeking HIV testing and treatment, and STI treatment etc.)
|
From baseline to 3-month
|
Patients' service preference
Time Frame: From baseline to 6-month
|
This outcome will be measured by the change in patients' indicated preference between centralized healthcare agencies and CHC when they have a list of hypothetical health conditions (including mental health issues, infectious diseases, when seeking HIV testing and treatment, and STI treatment etc.)
|
From baseline to 6-month
|
Patients' addiction and HIV-related service utilization
Time Frame: From baseline to 3-month
|
This outcome will be measured by the change in the number of recorded service encounters with service providers during the last three months.
Specifically, HIV/AIDS-related service utilization, including HIV testing and diagnosis will be documented at baseline and every follow-up point during the study period.
|
From baseline to 3-month
|
Patients' addiction and HIV-related service utilization
Time Frame: From baseline to 6-month
|
This outcome will be measured by the change in the number of recorded service encounters with service providers during the last three months.
Specifically, HIV/AIDS-related service utilization, including HIV testing and diagnosis will be documented at baseline and every follow-up point during the study period.
|
From baseline to 6-month
|
CHW's level of adherence to the working procedure
Time Frame: From baseline to 3-month
|
This outcome will be measured using the change in score of an adapted version of Primary Care Behavioral Health Provider Adherence Questionnaire (PPAQ).The scale consists of three subscales to measure the CHW's favorable, acceptable, and prohibited clinical behaviors as specified in the revised protocol (range: 20-100; higher score indicates higher level of adherence to the working procedure).
|
From baseline to 3-month
|
CHW's level of adherence to the working procedure
Time Frame: From baseline to 6-month
|
This outcome will be measured using the change in score of an adapted version of Primary Care Behavioral Health Provider Adherence Questionnaire (PPAQ).The scale consists of three subscales to measure the CHW's favorable, acceptable, and prohibited clinical behaviors as specified in the revised protocol (range: 20-100; higher score indicates higher level of adherence to the working procedure).
|
From baseline to 6-month
|
CHW's knowledge in harm reduction and HIV/AIDS will be assessed using a set of true-or-false questions based on the previously developed assessments
Time Frame: From baseline to 3-month
|
This outcome will be measured using the change in CHW's service knowledge, assessed using a set of true-or-false questions based on the previously developed assessments (range 0-17; higher score indicates' better knowledge in harm reduction and HIV/AIDS).
|
From baseline to 3-month
|
CHW's knowledge in harm reduction and HIV/AIDS will be assessed using a set of true-or-false questions based on the previously developed assessments
Time Frame: From baseline to 6-month
|
This outcome will be measured using the change in CHW's service knowledge, assessed using a set of true-or-false questions based on the previously developed assessments (range 0-17; higher score indicates' better knowledge in harm reduction and HIV/AIDS).
|
From baseline to 6-month
|
CHW's perceived challenges and administrative burdens in treating MMT patients
Time Frame: From baseline to 3-month
|
This outcome will be measured using change in CHW's perceived challenge and administrative burdens in treating MMT patients, from recruitment, retention to provide referrals/consultations, using the Connecticut Primary Care Survey items (range: 13-52; higher score indicates higher level of perceived challenges and burdens).
|
From baseline to 3-month
|
CHW's perceived challenges and administrative burdens in treating MMT patients
Time Frame: From baseline to 6-month
|
This outcome will be measured using change in CHW's perceived challenge and administrative burdens in treating MMT patients, from recruitment, retention to provide referrals/consultations, using the Connecticut Primary Care Survey items (range: 13-52; higher score indicates higher level of perceived challenges and burdens).
|
From baseline to 6-month
|
CHW's job satisfaction
Time Frame: From baseline to 3-month
|
This outcome will be measured using change in CHW's level of satisfaction with various aspects of their career and specialty, including practice in addictive treatment, working hours, working environment, and income (Bellingham's Job Satisfaction Survey; range: 17-65; higher score indicates higher level of job satisfaction).
|
From baseline to 3-month
|
CHW's job satisfaction
Time Frame: From baseline to 6-month
|
This outcome will be measured using change in CHW's level of satisfaction with various aspects of their career and specialty, including practice in addictive treatment, working hours, working environment, and income (Bellingham's Job Satisfaction Survey; range: 17-65; higher score indicates higher level of job satisfaction).
|
From baseline to 6-month
|
CHW's stigma associated with substance use
Time Frame: From baseline to 3-month
|
This outcome will be measured using change in CHW's substance use stigma using Substance Abuse Attitudes Survey (SAAS; range: 7-35; higher score indicates higher level of stigmatizing attitude towards patients who use substances).
|
From baseline to 3-month
|
CHW's stigma associated with substance use
Time Frame: From baseline to 6-month
|
This outcome will be measured using change in CHW's substance use stigma using Substance Abuse Attitudes Survey (SAAS; range: 7-35; higher score indicates higher level of stigmatizing attitude towards patients who use substances).
|
From baseline to 6-month
|
CHW's stigma associated with HIV
Time Frame: From baseline to 3-month
|
This outcome will be measured using change in CHW's HIV stigma using adapted items of Substance Abuse Attitudes Survey (adapted SAAS; range: 7-35; higher score indicates higher level of stigmatizing attitude towards patients living with HIV).
|
From baseline to 3-month
|
CHW's stigma associated with HIV
Time Frame: From baseline to 6-month
|
This outcome will be measured using change in CHW's HIV stigma using adapted items of Substance Abuse Attitudes Survey (adapted SAAS; range: 7-35; higher score indicates higher level of stigmatizing attitude towards patients living with HIV).
|
From baseline to 6-month
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MMT patients' mental health
Time Frame: From baseline to 3-month
|
This outcome will be measured using the change in the Patient Health Questionnaire (PHQ-9), without the last item measuring suicidal ideation (range 0-24; higher score indicates worse mental health).
|
From baseline to 3-month
|
MMT patients' mental health
Time Frame: From baseline to 6-month
|
This outcome will be measured using the change in the Patient Health Questionnaire (PHQ-9), without the last item measuring suicidal ideation (range 0-24; higher score indicates worse mental health).
|
From baseline to 6-month
|
MMT patients' heroin use
Time Frame: From baseline to 3-month
|
This outcome will be measured using the change in patients' self-reported heroin use in the past 30 days (yes/no).
|
From baseline to 3-month
|
MMT patients' heroin use
Time Frame: From baseline to 6-month
|
This outcome will be measured using the change in patients' self-reported heroin use in the past 30 days (yes/no).
|
From baseline to 6-month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 28, 2020
Primary Completion (Actual)
March 30, 2021
Study Completion (Actual)
August 31, 2022
Study Registration Dates
First Submitted
March 4, 2021
First Submitted That Met QC Criteria
March 10, 2021
First Posted (Actual)
March 15, 2021
Study Record Updates
Last Update Posted (Actual)
May 31, 2023
Last Update Submitted That Met QC Criteria
May 27, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- R34DA04378
- R34DA043783 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
After all data are de-identified, cleaned, and validated, and main findings are published, the study team will make study data available upon request with the scientific community.
Data sets will be made available to those who make a direct request to the PI and indicate the data will be used for the purposes of research.
No identifiers will be included in these data sets.
Depending on the request, data may be made available only in the form of codebooks and aggregated frequencies, to protect participant confidentiality.
The names of the communes where data are collected may not be released beyond the immediate study team to further protect the privacy of participants.
IPD Sharing Time Frame
Upon request
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Opioid-use Disorder
-
Hennepin Healthcare Research InstituteNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCRecruitingSubstance Use Disorder | Opioid Use Disorder, Moderate | Opioid Use Disorder, SevereUnited States
-
Aurora Health CareUniversity of Chicago; University of California, Santa Cruz; Rogers Behavioral...RecruitingSubstance Use | Methamphetamine-dependence | Opioid Use | Opioid-use Disorder | Cocaine Use Disorder | Cocaine Use | Methamphetamine AbuseUnited States
-
Hennepin Healthcare Research InstituteNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCRecruitingSubstance Use Disorders | Opioid Use Disorder, Moderate | Opioid Use Disorder, SevereUnited States
-
Vanderbilt University Medical CenterCompletedOpioid Use | Opioid-use DisorderUnited States
-
Emory UniversityNational Institute on Drug Abuse (NIDA); Georgia Institute of Technology; CUNYCompletedSubstance-Related Disorders | Substance Abuse, Intravenous | Substance Use Disorders | Opioid Use | Substance Abuse | Opioid-use Disorder | Opioid Use Disorder, Severe | Substance WithdrawalUnited States
-
Indiana UniversityCompletedOpioid Use | Opioid-use DisorderUnited States
-
University of ZurichCompletedOpioid Use, Unspecified With Other Opioid-induced DisorderSwitzerland
-
Virginia Commonwealth UniversityNational Institute on Drug Abuse (NIDA)CompletedOpioid-use Disorder | Cocaine Use Disorder | Healthy Controls | Marijuana Use DisorderUnited States
-
Albert Einstein College of MedicineNational Institute on Drug Abuse (NIDA); Pfizer; National Institutes of Health...Active, not recruitingTobacco Use Disorder | Opioid-use DisorderUnited States
-
Kyle KampmanNational Institute on Drug Abuse (NIDA)RecruitingOpioid-use Disorder | Cocaine Use DisorderUnited States
Clinical Trials on Service decentralization facilitation intervention
-
University of Colorado, DenverThe Leona M. and Harry B. Helmsley Charitable TrustActive, not recruitingDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Continuous Glucose MonitoringUnited States
-
University of MinnesotaRecruiting
-
University of KentuckyNational Cancer Institute (NCI)Enrolling by invitation
-
Assistance Publique Hopitaux De MarseilleNot yet recruiting
-
NHS Greater Glasgow and ClydeUniversity of GlasgowActive, not recruiting
-
Seattle Children's HospitalUniversity of WashingtonCompletedAttention Deficit Disorder With HyperactivityUnited States
-
University of Colorado, DenverCompleted
-
Universidade Federal de PernambucoUnknown
-
Ludwig-Maximilians - University of MunichKing's College London; University of Cambridge; Helmholtz Zentrum München; University...CompletedCancer | Chronic Heart Failure | Interstitial Lung Disease | COPD | BreathlessnessGermany